Scientific and ptactical conference with international participation:
«the 7th Scientific Session of the Institute of Gastroenterology of the National Academy of Medical Sciences of Ukraine.
Novel Technologies in Theoretical and Clinical Gastroenterology»
On June 13-14, 2019 Farmakom took part in the 7th Scientific Session of the Institute of Gastroenterology of the National Academy of Medical Sciences of Ukraine „Novel Technologies in Theoretical and Clinical Gastroenterology“ (City of Dnipro).
Leading scientists of Ukraine, as well as world-renoved scientists – prof. Mato de la Paz Jos ė Maria, Director General of the CIC bioGUNE (Spain), Dr. Sc. Medicine, Prof. Iu. M. Stepanov, Director of the SE “Institute of Gastroenterology of the NAMS of Ukraine”, Honored Doctor of Ukraine, Head of the PU “Association on Studying and Treatment of Digestive Organs Diseases in Ukraine”, Dr. Sc. Medicine, Prof., N. V. Kharchenko, Corresponding Member of the NAMS of Ukraine, Chairman of the Department of Gastroenterology, Dietology and Endoscopy of the Shupyk National Medical Academy of Postgraduate Education, and other opinion shapers took part in the conference.
During the conference prof. Olena Vadymivna Kolesnykova, Deputy Director for Scientific Work of the SE “L. T. Mala National Institute of Therapy of the NAMS of Ukraine”, Kharkiv, presented a report on the topic “Mechanisms of Fibrogenesis in case of non-alcoholic fatty liver disease: what do we know today?”. The report describes modern approaches to the mechanisms of liver fibrosis formation. A special attention is given to the role and the function of granule cells of the liver, processes of damaged liver regeneration. The light was shed upon the connection between liver fibrosis development and genetic and non-genetic factors. By the example of development of liver fibrosis in patients with non-alcoholic fatty liver disease positive effect of dietary supplement “Schisandrin®”, manufactured by Famrakom, on the reduction of the grade of fibrous changes in the liver, which emerge against the background of normalization of metabolic findings in patients with NAFLD, was described.